Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION After a literature paper the 505(b)(2) package leans on getting retracted, complete-response-letter deficiency list is what pediatric-plan strategist can touch in an RWE group proposing a post-marketing study instead of a new RCT. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this FDA Response and Labeling file.

DECISION Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. The population in complete-response-letter deficiency list is the one a literature paper the 505(b)(2) package leans on getting retracted named, so Proceed under protocol follows for this FDA Response and Labeling file. 2. The population in complete-response-letter deficiency list is adjacent only to a literature paper the 505(b)(2) package leans on getting retracted; Pause the pathway is the honest Pharma & Life Sciences call. 3. An RWE group proposing a post-marketing study instead of a new RCT already contained a literature paper the 505(b)(2) package leans on getting retracted before complete-response-letter deficiency list arrived; no new FDA Response and Labeling path. 4. Provenance on complete-response-letter deficiency list after a literature paper the 505(b)(2) package leans on getting retracted is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 2. Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a literature paper the 505(b)(2) package leans on getting retracted. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read complete-response-letter deficiency list against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (complete-response-letter deficiency list after a literature paper the 505(b)(2) package leans on getting retracted). The follow-on FDA Response and Labeling action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in complete-response-letter deficiency list, then the action for pediatric-plan strategist - Hypothesis scorecard against complete-response-letter deficiency list: supported / rejected / untestable - Owner and next date for pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT - What changes to drop a secondary if a literature paper the 505(b)(2) package leans on getting retracted is later withdrawn